Octapharma’s fibryga receives European label extension to treat acquired fibrinogen deficiency (AFD)

5 November 2019 - Octapharma announced today that the human fibrinogen concentrate fibryga has received approval for use in treatment of ...

Read more →

A severe shortage hits a drug used for cancer, immune disorders, epilepsy, causing canceled treatments and rationing

5 November 2019 - A severe shortage of immune globulin — a popular medicine used to treat epilepsy, cancer and ...

Read more →

FDA approves Octapharma’s Wilate for haemophilia A in adult and adolescent patients

8 October 2019 - Octapharma USA today announced the U.S. FDA has approved Wilate for treatment of adults and adolescents with ...

Read more →

Platelet rich plasma treatment is not classified as a drug, Health Canada says

27 July 2019 - Agency clarifies its position on controversial treatment made popular by superstar athletes. ...

Read more →

Esperoct is now approved in Canada for the treatment of haemophilia A in both children and adults

12 July 2019 - New treatment can help Canadians living with haemophilia A better manage their bleeding episodes ...

Read more →

ADMA Biologics receives FDA approval for license transfers for Bivigam and Nabi-HB

8 July 2019 - All aspects of the Biotest Therapy Business Unit acquisition are successfully completed. ...

Read more →

Grifols announces FDA approval of Xembify, 20% subcutaneous immunoglobulin for primary immunodeficiencies

4 July 2019 - Xembify is Grifols’ first 20% subcutaneous immunoglobulin for the treatment of primary immunodeficiencies. ...

Read more →

Esperoct (turoctocog alfa pegol, N8-GP) approved in the EU

20 June 2019 - Novo Nordisk today announced that the European Commission has granted marketing authorisation for Esperoct for the treatment ...

Read more →

FDA approves prior approval supplement for Bivigam

10 May 2019 - ADMA Biologics announces that the U.S. FDA has approved the Company’s prior approval supplement for Bivigam (immune ...

Read more →

PHARMAC fully funding innovative improvements in haemophilia treatment

30 April 2019 - PHARMAC has today provided haemophilia patients fully funded access to new innovative treatment options which will ...

Read more →

FDA approves Asceniv, a novel intravenous immune globulin

1 April 2019 - Approved for use in the treatment of primary humoral immunodeficiency disease in adults and adolescents (12 to ...

Read more →

Decision to make changes to funded haemophilia treatments

8 March 2019 - PHARMAC is pleased to announce changes to funded haemophilia treatments that will result in two new ...

Read more →

Novo Nordisk receives US FDA approval of Esperoct (turoctocog alfa pegol, N8-GP)

19 February 2019 - Novo Nordisk today announced that the US FDA has approved the biologics license application for Esperoct ...

Read more →

Proposal for changes to funded haemophilia treatments

29 January 2019 - PHARMAC is proposing to make changes to the funding of haemophilia treatments from 1 May 2019, ...

Read more →

ADMA Biologics submits response and provides supplemental information to FDA for Bivigam complete response letter

7 January 2019 - ADMA Biologics announces that the Company has submitted responses to the U.S. FDA complete response letter received ...

Read more →